Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 6
Submit an article Journal homepage
75
Views
27
CrossRef citations to date
0
Altmetric
Review

The search for the ideal SERM

Barbara Dunn Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA. [email protected]
,
Marietta Anthony Department of Pharmacology, Women’s Health Research, Georgetown University Medical Center, Washington, District of Columbia 20007, USA. [email protected]
&
Banu Arun Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. [email protected]
Pages 681-691 | Published online: 25 Feb 2005

Bibliography

  • ••CLEMONS MGOSS P: Estrogen and the risk of breast cancer. N Engl. I Med. (2001) 344(4):276–285.
  • HANKINSON SE, WILLETT WC, MANSON JE et al.: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. Nati Cancer Inst. (1998) 90(17):1292–1299.
  • CAULEY JA, LUCAS FL, KULLER LH et al.: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. (1999) 130(4, Part 1):270–277.
  • •COLDITZ GA, HANKINSON SE, HUNTER DJ et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl. Med. (1995) 332(24):1589–1593.
  • ••COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet (1997) 350(9084):1047–1059.
  • •SCHAIRER C, LUBIN J, TROISI R et al: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA (2000) 283(4):485–491.
  • FURR BJORDAN V: The pharmacology and clinical uses of tamoxifen. Pharma. Ther. (1984) 25:127–205.
  • ISSANDOU M, FAUCHER C, BAYARD FDARBON JM: Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res. (1990) 50:5845–5850.
  • KANG Y, CORTINA R, PERRY RR: Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cells. Natl. Cancer Inst. (1996) 88:279–284.
  • •CUZCICK J: Chemoprevention of breast cancer with tamoxifen. IARC Sci. Publ. (1996) 136:95–105.
  • FERLINI C, SCAMBIA G, MARONE M et al.: Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br. Cancer (1999) 70(2):257–263.
  • ••JORDAN V: Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethylbenzantracene (DMBA)-induced rat mammary carcinoma model. Steroid Biochem. (1974):354. Abstract.
  • •JORDAN VC, ALLEN K Evaluation of the antitumor activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Ear: Cancer. (1980) 1692:239–251.
  • JORDAN V, ALLEN K, DIX C: Pharma-cology of tamoxifen in laboratory animals. Cancer Treat. Rep. (1980) 64 (6-7) : 175–159.
  • JORDAN V, LABABIDI MMIRECKI D: Anti-oestrogenic and anti-tumor properties of prolonged tamoxifen therapy in C3H/ OUJ mice. Eur. Cancer. (1990) 26(6):718–721.
  • •JORDAN VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res. Treat. (1983) 3(Suppl.):S73–86.
  • JORDAN VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. Cancer. (1976) 12(6):419–424.
  • NAYFIELD S, KARP J, FORD L et al: Potential role of tamoxifen in prevention of breast cancer. Nati Cancer Inst. (1991) 83:1450–1459.
  • •FORNANDER T, RUTQVIST LE, CEDERMARK B et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet (1989) 1(8630):117–120.
  • Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet (1987) 2(8552):171–175.
  • 'NOLVADEX' ADJUVANT TRIAL ORGANISATION: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer (1988) 57(6):608–611.
  • CRC ADJUVANT BREAST TRIAL WORKING PARTY: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br. J. Cancer (1988) 57(6):604–607.
  • ••FISHER B, DIGNAM J, BRYANT J et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Nati Cancer Inst. (1996) 88(21):1529–1542.
  • ••EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351(9114):1451–1467.
  • ARUN B, HORTOBAGYI GN: Progress in breast cancer chemoprevention. Endocr. Relat. Cancer (2002) 9(1):15–32.
  • ••FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Nati Cancer Inst. (1998) 90(18):1371–1388.
  • ANZANO MA, PEER CW, SMITH JM et al.: Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. Natl. Cancer Inst. (1996) 88(2):123–125.
  • BUZDAR AU, MARCUS C, HOLMES F eta/ Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology (1988) 45(5):344–345.
  • GRADISHAR W, GLUSMAN J, LU Yet al.: Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer (2000) 88(9):2047–2053.
  • ••CUMMINGS SR, ECKERT S, KRUEGER KA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA (1999) 281(23):2189–2197.
  • ••ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 282(7):637–645.
  • ••LIPPMAN ME, KRUEGER KA, ECKERT S et al.: Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J. Clin. Oncol. (2001) 19(12):3111–3116.
  • JORDAN VC, GLUSMANJE, ECKERT S et al.: Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter double blind, randomized trials in12,000 postmenopausal women. Proc.Am. Cancer Soc. Clin. Oncol. (1998) 17:122a (abstract 466).
  • •DUNN BK, FORD LG: Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT). Eur. J. Cancer (2000) 36\(Suppl. 4):S49–50.
  • BUZDAR AU, KAU S, HORTOBAGYI GN et al.: Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. (1994) 33(4):313–316.
  • RAUSCHNING W, PRITCHARD KI: Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res. Treat. (1994) 31(1):83–94.
  • HAYES DF, VAN ZYL JA, HACKING A et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. (1995) 13(10):2556–2566.
  • •GRADISHAR WJ, JORDAN VC: Clinical potential of new antiestrogens. Clin. Oncol. (1997) 15(2):840–852.
  • MUNSTER PN, BUZDAR A, DHINGRA K et al.: Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. Clin. Oncol. (2001) 19(7):2002–2009.
  • •BUZDAR AU, HORTOBAGYI GN: Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. Clin. Oncol. (1998) 16(1):348–353.
  • •O'REGAN RIVI, CISNEROS A, ENGLAND GM et al.: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Nati Cancer Inst. (1998) 90(20):1552–1558.
  • ••FISHER B, COSTANTINO JP, REDMOND CK et al: Endometrial cancer in tamoxifen treated breast cancer patients. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP). J. Natl. Cancer Inst. (1994) 86:527–537.
  • ••VAN LEEUWEN FE, BENRAADT J, COEBERGH JVV et al.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet (1994) 343(8895):448–452.
  • •RUTQVIST LE, JOHANSSON H, SIGNOMKLAO T et al.: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. Nati Cancer Inst. (1995) 87(9):645–651.
  • SHAPIRO C, LRECHT A: Side effects of adjuvant treatment of breast cancer. N Engl. J. Med. (2001) 344(26):1997–2008.
  • •KEDAR RP, BOURNE TH, POWLES TJ et al.: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 343(8909):1318–1321.
  • KURMAN RJ, KAMINSKI PF, NORRIS HJ: The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients. Cancer. (1985) 56(2):403–412.
  • SHERMAN Al, BROWN S: The precursors of endometrial carcinoma. Am. J. Obster Cynecol. (1979) 135(7):947–956.
  • ••SHANG Y, BROWN M: Molecular determinants for the tissue specificity of SERMs. Science (2002) 295(5564):2465–2468.
  • IARC on tamoxifen. Environ. Health Perspect. (1996) 104(7):688.
  • NEWCOMB PA, SOLOMON C, WHITE E: Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res. Treat. (1999) 53(3):271–277.
  • COOK LS, WEISS NS, PHARRIS-CIUREJ N eral. Colorectal cancer following tamoxifen therapy for breast cancer (United States). Cancer Causes Control (2001) 12(5):405–410.
  • RIGGS BL, KHOSLA S, MELTON LJ 3rd: A unitary model for involutional osteoporosis: estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. Bone Miner. Res. (1998) 13(5):763–773.
  • •CUMMINGS SR, BROWNER WS, BAUER D et al.: Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl. I Med. (1998) 339(11):733–738.
  • •LUFKIN EG, WAHNER HW, O'FALLON WM et al.: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. (1992) 117(1):1–9.
  • Drugs for prevention and treatment of postmenopausal osteoporosis. Med. Lett. Drugs Ther. (2000) 42:97–100.
  • ••CAULEY JA, BLACK DM, BARRETT-CONNOR E et al.: Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/ Progestin Replacement Study (HERS). Am. J. Med. (2001) 110(6):442–450.
  • ••NTH CONSENSUS DEVELOPMENT PANEL ON OPTIMAL CALCIUM INTAKE: NIH Consensus conference. Optimal calcium intake. "AMA (1994) 272(24):1942–1948.
  • •HOSKING D, CHILVERS CE, CHRISTIANSEN C et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl. I Med. (1998) 338(8):485–492.
  • •BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 348(9041):1535–1541.
  • MORTENSEN L, CHARLES P, BEKKER PJ et al.: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. I Clin. Endocrinol. Metab. (1998) 83(2):396–402.
  • ••DELMAS PD, BJARNASON NH, MITLAK BH et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl. J. Med. (1997) 337(23):1641–1647.
  • •LOVE RR, MAZESS RB, BARDEN HS et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl. J. Med. (1992) 326(13):852–856.
  • KRISTENSEN B, EJLERTSEN B, DALGAARD P et al.: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. I Clin. Oncol. (1994) 12(5):992–997.
  • CUSHMAN M, LEGAULT C, BARRETT-CONNOR E et al.: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation (1999) 100(7):717–722.
  • RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl. I Med. (1997) 336(14):973–979.
  • STAMPFER MJ, COLDITZ GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med. (1991) 20(1):47–63.
  • GRADY D, RUBIN SM, PETITTI DB et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. (1992) 117(12):1016–1037.
  • PSATY BM, HECKBERT SR, ATKINS D et al.: The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch. Intern. Med. (1994) 154(12):1333–1339.
  • •MENDELSOHN ME, KARAS RH: The protective effects of estrogen on the cardiovascular system. N Engl. I Med. (1999) 340(23):1801–1811.
  • ••HULLEY S, GRADY D, BUSH T et al.:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. "AMA (1998) 280(7):605–613.
  • •HERRINGTON DM, REBOUSSIN DM, BROSNIHAN KB et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl. I Med. (2000) 343(8):522–529.
  • GRODSTEIN F, MANSON JE, STAMPFER MJ: Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann. Intern. Med. (2001) 135(1):1–8.
  • •• THE WOMEN'S HEALTH INITIATIVE STUDY GROUP: Design of the Women's Health Initiative clinical trial and observational study. Control. Clin. Trials. (1998) 19(1):61–109.
  • ••MOSCA L, CONNOR EN W: Design and Methods of the Raloxifene Use for the Heart (RUTH) Study. Am. I Cardiol. (2001) 88(392–395).
  • CUSHMAN M, COSTANTINO JP, TRACY RP et al.: Tammdfen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler. Thromb. Vasc. Biol. (2001) 21(2):255–261.
  • REIS SE, COSTANTINO JP, WICKERHAM DL et al.: Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. I Nati Cancer Inst. (2001) 93(1):16–21.
  • WALSH BW, KULLER LH, WILD RA et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. "AMA (1998) 279(18):1445–1451.
  • ••BARRETT-CONNOR E, GRADY D, SASHEGYI A et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. "AMA (2002) 287(7):847–857.
  • EVANS DA: Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. (1990) 68(2):267–289.
  • SHUGHRUE PJ, LANE MVMERCHENTHALER I: Comparative distribution of estrogen receptor-alpha and - beta mRNA in the rat central nervous system. Comp. Neurol. (1997) 388(4):507–525.
  • TORAN-ALLERAND CD, MIRANDA RC, BENTHAM WD et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA (1992) 89(10):4668–4672.
  • SUMMER BE, FINK G: Estrogen increases the density of 5-hydroxytryptamine (2A) receptors in cerebral cortex and nucleus accumbens in the female rat. I Steroid Biochem. Mol. Biol. (1995) 54(1-2):15–20.
  • BECKER JB: Oestrogen effects on dopaminergic function in striatum. Novartis Found. Symp. (2000) 230:134–145.
  • HERBISON AE, SIMONIAN SX, THANKY NR, BICKNELL RJ: Oestrogen modulation of noradrenaline neurotransmission. Novartis Found. Symp. (2000) 230:74–85.
  • YAFFE K, GRADY D, PRESSMAN ACUMMINGS S: Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. I Am. Ceriatr. Soc. (1998) 46(7):816–821.
  • KAMPEN DLSHERWIN BB: Estrogen use and verbal memory in healthy postmenopausal women. °Intel-. Cynecol. (1994) 83(6):979–983.
  • KIMURA D: Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm. Behav. (1995) 29(3):312–321.
  • ••BARRETT-CONNOR E, KRITZ-SILVERSTEIN D: Estrogen replacement therapy and cognitive function in older women. JAMA (1993) 269(20):2637–2641.
  • CAMPBELL S, WHITEHEAD M: Oestrogen therapy and the menopausal syndrome. Clin. Obstet. Cynaecol. (1977) 4(1):31–47.
  • FEDOR-FREYBERGH P: The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet. Cynecol. Scand. Suppl. (1977) 64:1–91.
  • PHILLIPS SM, SHERWIN BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuro-endocrinology(1992) 17(5):485–495.
  • DUKA T, TASKER R, MCGOWAN JF: The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females. Psychopharmacology (Ben). (2000) 149(2):129–139.
  • POLO-KANTOLA P, ERKKOLA R, IRJALA K et al.: Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Feral. Steril. (1999) 71(5):873–880.
  • RESNICK SM, METTER EJ, ZONDERMAN AB: Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology(1997) 49(6):1491–1497.
  • •KAWAS C, RESNICK S, MORRISON A et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology(1997) 48(6):1517–1521.
  • ••YAFFE K, SAWAYA G, LIEBERBURG IGRADY D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA (1998) 279(9):688–695.
  • •HENDERSON VW, PAGANINI-HILL A, MILLER BL et al.: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology (2000) 54(2):295–301.
  • ••MULNARD RA, COTMAN CW, KAWAS C et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's disease Cooperative Study. JAMA (2000) 283(8):1007–1015.
  • PAGANINI-HILL A, CLARK LJ: Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. (2000) 64(2):165–176.
  • BREUER BANDERSON R: The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health. (2000) 31(1):71–85.
  • ••ERNST T, CHANG L, COORAY D et al.: The effects of tamoxifen and estrogen on brain metabolism in elderly women. Natl. Cancer Inst. (2002) 94(8):592–597.
  • NICKELSEN T, LUFKIN EG, RIGGS BL, COX DA, CROOK TH: Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuro-endocrinology (1999) 24(1):115–128.
  • ••YAFFE K, KRUEGER K, SARKAR Set al.: Cognitive function in postmenopausal women treated with raloxifene. N Engl. J. Med. (2001) 344(16):1207–1213.
  • GOLD EB, STERNFELD B, KELSEY JL et al.: Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am. J. Epidemiol. (2000) 152(5):463–473.
  • HAY AG, BANCROFT J, JOHNSTONE EC: Affective symptoms in women attending a menopause clinic. Br. J. Psychiatry (1994) 164(4):513–516.
  • SHERMAN BM, KORENMAN SG: Hormonal characteristics of the human menstrual cycle throughout reproductive life. Clin. Invest. (1975) 55(4):699–706.
  • TATARYN IV, LOMAX P, MELDRUM DR et al.: Objective techniques for the assessment of postmenopausal hot flashes. Cynecol. (1981) 57(3):340–344.
  • GOLDMAN GA, KAPLAN B, LEISEROWITZ DM et al.: Compliance with hormone replacement therapy in postmenopausal women. A comparative study. Clin. Exp. °Intel-. Cynecol. (1998) 25(1-2):18–19.
  • NACHTIGALL LE: Enhancing patient compliance with hormone replacement therapy at menopause. Obstet. Cynecol. (1990) 75(4, Suppl.):77S-80S; Discussion 81S–83S.
  • HAHN RG, NACHTIGALL RD, DAVIES TC: Compliance difficulties with progestin-supplemented estrogen replacement therapy. J. Fam. Pract. (1984) 18(3):411–414.
  • PILON D, CASTILLOUX AM, LELORIER J: Estrogen replacement therapy: determinants of persistence with treatment. °Intel-. Cynecol. (2001) 97(1):97–100.
  • ••VERONESI U, MAISONNEUVE P, COSTA A et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet (1998) 352(9122):93–97.
  • ”DECENSI A, BONANNI B, GUERRIERI-GONZAGA A et al: Chemoprevention of breast cancer: the Italian experience. J. Cell. Biochem. (2000) 77(S34):84–96.
  • ••DECENSI A, ROBERTSON C, ROTMENSZ N et al.: Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br. J. Cancer. (1998) 78(5):572–578.
  • ••GUERRIERI-GONZAGA A, GALLI A, ROTMENSZ N, DECENSI A: The Italian Breast Cancer Prevention Trial with Tamoxifen: findings and new perspectives. Ann. NY Acad. ScL (2001) 949(1):113–122.
  • ••COBLEIGH M: Hormone replacement therapy in breast cancer survivors. In: Disease of the Breast. Updates. J. Harris and M. Lippman (Ed.), (1997):
  • SWAINS, SANTEN H, BURGER K, PRITCHARD K: Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2: hormone replacement therapy and breast cancer. Conference held in Charlottesville, Virginia, September 21–23, 1997. Oncology (1999): 245–267.
  • COLDITZ GA: Estrogen replacement therapy for breast cancer patients. Oncology (Huntingt) (1997) 11(10):1491–1494, 1497; Discussion 1498, 1501.
  • •LOVE RR, CAMERON L, CONNELL BLLEVENTHAL H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Intern. Med. (1991) 151(9):1842–1847.
  • DAY R, GANZ PA, COSTANTINO JP et al.: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Oncol. (1999) 17(9):2659–2669.
  • DAVIES GC, HUSTER WJ, LU Y, PLOUFFE L, JR LAKSHMANAN M: Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Cynecol. (1999) 93(4):558–565.
  • BARAKAT RR: The effect of tamoxifen on the endometrium. Oncology (Llentingt) (1995) 9(2):129–134; Discussion 139–140, 142.
  • ••THE WRITING GROUP FOR THE PEPI TRIAL: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA (1995) 273(3):199–208.
  • ••VVEIDERPASS E, BARON JA, ADAMI HO et al.: Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet (1999) 353(9167):1824–1828.
  • BLACK LJ, SATO M, ROWLEY ER et al.: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Clin. Invest. (1994) 93(1):63–69.
  • BOSS SM, HUSTER WJ, NEILDJA et al.: Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am.j Obstet. Cynecol. (1997) 177(6):1458–1464.
  • VESSEY M, MANT D, SMITH A, YEATES D: Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br. Med. .1. (Clin. Res. Ed.) (1986) 292(6519):526.
  • ••WORLD HEALTH ORGANIZATION: Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet (1995) 346(8990):1575–1582.
  • ••DALY E, VESSEY MP, HAWKINS MM et al.: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet (1996) 348(9033):977–980.
  • ••JICK H, DERBY LE, MYERS MW, VASILAKIS C, NEWTON KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet (1996) 348(9033):981–983.
  • GRADY D, VVENGER NK, HERRINGTON D et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med. (2000) 132(9):689–696.
  • GRODSTEIN F, STAMPFER MJ, GOLDHABER SZ et al.: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet (1996) 348(9033):983–987.
  • VISCOLI CM, BRASS LM, KERNAN WN et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl. Med. (2001) 345(17):1243–1249.
  • •FISHER B, COSTANTINO J, REDMOND C et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl. Med. (1989) 320(8):479–484.
  • •PRITCHARD KI, PATERSON AH, PAUL NA et al.: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J. Clin. Oncol. (1996) 14(10):2731–2737.
  • •PALMIERI C, CHENG GJ, SAJI S et al.: Estrogen receptor beta in breast cancer. Endocr: Relat. Cancer (2002) 9 (1):1–13.
  • ••GAIL MH, COSTANTINO JP, BRYANT J et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Nati Cancer Inst. (1999) 91(21):1829–1846.

Websites

  • www.NHLBI.nih.gov/whi/hrt-en.htm National Institutes of Health. National Heart LaBI: Women's Health Initiative. (2000).
  • www.fda.gov./cder/news/cebackground.htm FDA Backgrounder on Conjugated Estrogens.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.